10x Genomics [TXG] vs Teladoc Health [TDOC] Detailed Stock Comparison

10x Genomics

NASDAQ
Loading...

Teladoc Health

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: 10x Genomics wins in 7 metrics, Teladoc Health wins in 11 metrics, with 0 ties. Teladoc Health appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric10x GenomicsTeladoc HealthBetter
P/E Ratio (TTM)-8.55-1.5010x Genomics
Price-to-Book Ratio2.051.12Teladoc Health
Debt-to-Equity Ratio11.2272.7810x Genomics
PEG Ratio0.050.02Teladoc Health
EV/EBITDA-11.07103.1410x Genomics
Profit Margin (TTM)-13.13%-8.16%Teladoc Health
Operating Margin (TTM)-2.63%-7.29%10x Genomics
Return on Equity-11.30%-14.18%10x Genomics
Return on Assets (TTM)-9.45%-3.57%Teladoc Health
Free Cash Flow (TTM)$-6.73M$169.63MTeladoc Health
1-Year Return-28.66%-9.02%Teladoc Health
Price-to-Sales Ratio (TTM)2.460.63Teladoc Health
Enterprise Value$1.23B$1.95BTeladoc Health
EV/Revenue Ratio1.900.77Teladoc Health
Gross Profit Margin (TTM)72.34%69.85%10x Genomics
Revenue per Share (TTM)$5$15Teladoc Health
Earnings per Share (Diluted)$-0.70$-1.1510x Genomics
Beta (Stock Volatility)2.051.91Teladoc Health
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

10x Genomics vs Teladoc Health Stock Performance Analysis

Loading Price Chart...

10x Genomics
Teladoc Health
10x Genomics Stock Overview | Teladoc Health Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
10x Genomics-8.23%-0.77%-16.73%-2.68%53.03%-18.25%
Teladoc Health-2.33%8.28%6.76%3.72%15.77%-12.08%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
10x Genomics-28.66%-54.65%-92.91%-77.81%-77.81%-77.81%
Teladoc Health-9.02%-63.86%-96.22%-53.50%-70.11%-70.11%

News Based Sentiment: 10x Genomics vs Teladoc Health

10x Genomics

News based Sentiment: MIXED

October brought a strong Q3 earnings beat and positive analyst revisions for 10x Genomics, but these were tempered by a negative full-year EPS forecast and mixed technical indicators. This creates a complex investment picture with both opportunities and risks, making it a significant month for the company.

View 10x Genomics News Sentiment Analysis

Teladoc Health

News based Sentiment: MIXED

October was a month of conflicting signals for Teladoc, with continued financial challenges offset by a surprising stock surge and strategic initiatives. The regulatory environment remains a key risk, creating a mixed outlook for investors. The combination of positive market reaction and underlying financial concerns makes this a significant month for the company.

View Teladoc Health News Sentiment Analysis

Performance & Financial Health Analysis: 10x Genomics vs Teladoc Health

MetricTXGTDOC
Market Information
Market Cap i$1.59B$1.59B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i2,746,6608,888,160
90 Day Avg. Volume i2,469,4205,961,557
Last Close$11.60$8.37
52 Week Range$6.78 - $20.92$6.35 - $15.21
% from 52W High-44.55%-44.97%
All-Time High$208.99 (Jun 28, 2021)$308.00 (Feb 15, 2021)
% from All-Time High-94.45%-97.28%
Growth Metrics
Quarterly Revenue Growth0.13%-0.02%
Quarterly Earnings Growth0.13%-0.02%
Financial Health
Profit Margin (TTM) i-0.13%-0.08%
Operating Margin (TTM) i-0.03%-0.07%
Return on Equity (TTM) i-0.11%-0.14%
Debt to Equity (MRQ) i11.2272.78
Cash & Liquidity
Book Value per Share (MRQ)$6.21$8.05
Cash per Share (MRQ)$3.59$3.85
Operating Cash Flow (TTM) i$66.95M$303.43M
Levered Free Cash Flow (TTM) i$58.22M$209.72M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: 10x Genomics vs Teladoc Health

MetricTXGTDOC
Price Ratios
P/E Ratio (TTM) i-8.55-1.50
Forward P/E i-10.45-10.12
PEG Ratio i0.050.02
Price to Sales (TTM) i2.460.63
Price to Book (MRQ) i2.051.12
Market Capitalization
Market Capitalization i$1.59B$1.59B
Enterprise Value i$1.23B$1.95B
Enterprise Value Metrics
Enterprise to Revenue i1.900.77
Enterprise to EBITDA i-11.07103.14
Risk & Other Metrics
Beta i2.051.91
Book Value per Share (MRQ) i$6.21$8.05

Financial Statements Comparison: 10x Genomics vs Teladoc Health

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TXGTDOC
Revenue/Sales i$154.88M$629.37M
Cost of Goods Sold i$49.44M$196.83M
Gross Profit i$105.45M$432.54M
Research & Development i$64.25M$69.96M
Operating Income (EBIT) i$-48.53M$-54.94M
EBITDA i$-32.89M$50.34M
Pre-Tax Income i$-33.51M$-111.27M
Income Tax i$852,000$-18.26M
Net Income (Profit) i$-34.36M$-93.01M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TXGTDOC
Cash & Equivalents i$377.06M$679.62M
Total Current Assets i$579.73M$1.07B
Total Current Liabilities i$107.90M$401.77M
Long-Term Debt i$70.63M$1.03B
Total Shareholders Equity i$706.90M$1.42B
Retained Earnings i$-1.50B$-16.36B
Property, Plant & Equipment i$55.58M$27.67M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TXGTDOC
Operating Cash Flow i$35.44M$89.56M
Capital Expenditures i$-1.89MN/A
Free Cash Flow i$32.46M$31.63M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTXGTDOC
Shares Short i17.35M23.82M
Short Ratio i7.585.40
Short % of Float i0.22%0.15%
Average Daily Volume (10 Day) i2,746,6608,888,160
Average Daily Volume (90 Day) i2,469,4205,961,557
Shares Outstanding i122.29M173.41M
Float Shares i109.33M174.74M
% Held by Insiders i0.02%0.01%
% Held by Institutions i1.05%0.74%

Dividend Analysis & Yield Comparison: 10x Genomics vs Teladoc Health

MetricTXGTDOC
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A